David Urech
Fondatore presso Numab Therapeutics AG
Posizioni attive di David Urech
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Numab Therapeutics AG
 Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | Direttore/Membro del Consiglio | 01/01/2011 | - |
| Amministratore Delegato | 01/01/2011 | - | |
| Fondatore | 01/01/2011 | - | |
| Direttore Tecnico/Scientifico/R&S | 01/01/2011 | - |
Storia della carriera di David Urech
Precedenti posizioni note di David Urech
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Direttore Tecnico/Scientifico/R&S | - | - |
Formazione di David Urech
| University of Zurich | Undergraduate Degree |
| University of Basel | Doctorate Degree |
Statistiche
Distribuzione geografica
| Svizzera | 5 |
Posizioni
| Chief Tech/Sci/R&D Officer | 2 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Settori
| Commercial Services | 3 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Commercial Services |
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | Commercial Services |
- Borsa valori
- Insiders
- David Urech
- Esperienza
